Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 669

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 669
---
#### Outside Date
”); provided, however, that the right to terminate this Agreement under this Section 10.1(c) shall not be available to any Party that has materially breached any of its representations, warranties, covenants or agreements under this Agreement (including, with respect to the Company, any breach by ParentCo) if such material breach is the primary cause of or has resulted in the failure of the transactions contemplated by this Agreement to be consummated on or before such date;”

3. Effect on BCA . Except as set forth in this Amendment, all of the terms, covenants, agreements, and conditions of the BCA shall remain in full force and effect in accordance with its original terms.

4. Prior Agreements . This Amendment supersedes all prior or contemporaneous negotiations, commitments, agreements and writings with respect to the subject matter hereof, all such other negotiations, commitments, agreements and writings will have no further force or effect, and the Parties to any such other negotiation, commitment, agreement or writing will have no further rights or obligations thereunder.

5. Governing Law . This Amendment shall be governed by and construed in accordance with the laws of the State of New York without regard to any conflicts of laws principles thereto that would call for the application of the laws of any other jurisdiction.

6. Counterparts, Facsimile Signatures . This Amendment may be executed in any number of identical counterparts, each of which, for all purposes, is to be deemed an original, and all of which

<div align='center'>A-77</div>

TABLE OF CONTENTS

constitute, collectively, one and the same Amendment. Signatures transmitted by electronic means such as email or facsimile shall have the same legal effect as an original signature hereto.

<div align='center'>[Signature page to follow.]

A-78</div>

TABLE OF CONTENTS

IN WITNESS WHEREOF, this Second Amendment to Business Combination Agreement has been duly executed and delivered by each of the Parties as of the date first above written.

#### SPAC

#### Iris Acquisition Corp
By:

/s/ Sumit Mehta

Name:

Sumit Mehta

Title:

Chief Executive Officer

### COMPANY

#### Liminatus Pharma, LLC
By:

/s/ Chris Kim

Name:

Chris Kim

Title:

CEO, Secretary and Treasurer

### PARENTCO

#### Iris Parent Holding Corp.
By:

/s/ Chris Kim

Name:

Chris Kim

Title:

CEO, Secretary